Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

We retrospectively analyzed 70 patients with classical Hodgkin lymphoma (cHL) who were treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radiotherapy to assess the influence of the soluble interleukin-2 receptor (sIL-2R) level at diagnosis on the clinical outcome. Receiver operating characteristic analyses determined that the optimal cutoff value of the sIL-2R level for progression-free survival (PFS) was 2490 U/mL. Using this cutoff value, patients were classified into low (n = 46) and high (n = 24) sIL-2R groups. The patients in the high sIL-2R group exhibited a significantly inferior PFS (44.1% vs. 90.4% at 5 years, P < 0.001) and overall survival (OS) (67.6% vs. 94.7% at 5 years, P = 0.001) compared with those in the low sIL-2R group. Multivariate analysis showed that a high sIL-2R level was an independent prognostic factor for PFS after adjusting for stage, white blood cell, hemoglobin, and B symptoms, and also OS after adjusting for age and stage (hazard ratio (HR) 6.49, P < 0.001 and HR 5.98, P = 0.009, respectively). In patients with advanced-stage cHL, a high sIL-2R level predicted 5-year PFS even after adjustment for international prognostic score > 4 (HR 6.00, P = 0.007). These results demonstrate that the sIL-2R level can be a useful prognostic factor in patients with cHL treated with ABVD with or without radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93(5):704–715. https://doi.org/10.1002/ajh.25071

    Article  PubMed  Google Scholar 

  2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(27):4199–4206. https://doi.org/10.1200/jco.2010.29.8018

    Article  Google Scholar 

  4. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Boll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385(9976):1418–1427. https://doi.org/10.1016/s0140-6736(14)61469-0

    Article  CAS  PubMed  Google Scholar 

  5. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478–1484. https://doi.org/10.1056/nejm199211193272102

    Article  CAS  PubMed  Google Scholar 

  6. Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M (2016) Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol Off J Am Soc Clin Oncol 34(11):1175–1181. https://doi.org/10.1200/jco.2015.62.4817

    Article  CAS  Google Scholar 

  7. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14(10):943–952. https://doi.org/10.1016/s1470-2045(13)70341-3

    Article  PubMed  Google Scholar 

  8. Smith KA (1988) Interleukin-2: inception, impact, and implications. Science (New York, NY) 240(4856):1169–1176

    Article  CAS  Google Scholar 

  9. Kawaguchi Y, Nakamaki T, Abe M, Baba Y, Murai S, Watanuki M, Arai N, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Harada H, Saito B (2018) Association of soluble interleukin-2 receptor and C-reactive protein with the efficacy of bendamustine salvage treatment for indolent lymphomas and mantle cell lymphoma. Acta Haematol 139(1):12–18. https://doi.org/10.1159/000484711

    Article  CAS  PubMed  Google Scholar 

  10. Kusano Y, Yokoyama M, Terui Y, Inoue N, Takahashi A, Yamauchi H, Tsuyama N, Nishimura N, Mishima Y, Takeuchi K, Hatake K (2017) High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J 7(9):e614. https://doi.org/10.1038/bcj.2017.96

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y (2017) Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology 22(9):521–526. https://doi.org/10.1080/10245332.2017.1312204

    Article  CAS  PubMed  Google Scholar 

  12. Tomita N, Suzuki T, Miyashita K, Yamamoto W, Motohashi K, Tachibana T, Takasaki H, Kawasaki R, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Taguchi J, Fujimaki K, Fujita H, Sakai R, Fujisawa S, Motomura S, Kawamoto K, Sone H, Takizawa J (2016) The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma. Leuk Lymphoma 57(12):2763–2770. https://doi.org/10.1080/10428194.2016.1195498

    Article  CAS  PubMed  Google Scholar 

  13. Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y (2017) Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. Leuk Lymphoma 58(2):316–323. https://doi.org/10.1080/10428194.2016.1190975

    Article  CAS  PubMed  Google Scholar 

  14. Shiratori S, Kosugi-Kanaya M, Shigematsu A, Kobayashi H, Yamamoto S, Kobayashi N, Iwasaki H, Mori A, Kunieda Y, Yutaka T, Kurosawa M, Kakinoki Y, Endo T, Kondo T, Hashino S, Teshima T (2015) Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 56(9):2592–2597. https://doi.org/10.3109/10428194.2014.1001985

    Article  CAS  PubMed  Google Scholar 

  15. Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20(3):526–533. https://doi.org/10.1093/annonc/mdn677

    Article  CAS  PubMed  Google Scholar 

  16. Umino K, Fujiwara SI, Minakata D, Yamamoto C, Meguro A, Matsuyama T, Sato K, Ohmine K, Izumi T, Muroi K, Kanda Y (2018) Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma 60:1–8. https://doi.org/10.1080/10428194.2018.1504939

    Article  CAS  Google Scholar 

  17. Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM (2013) Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 19(24):6812–6819. https://doi.org/10.1158/1078-0432.ccr-13-1879

    Article  CAS  PubMed  Google Scholar 

  18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 25(5):579–586. https://doi.org/10.1200/jco.2006.09.2403

    Article  Google Scholar 

  19. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

    Article  CAS  Google Scholar 

  20. Javanmardi F, Saki-Malehi A, Ahmadzadeh A, Rahim F (2018) Assessing prognostic factors in Hodgkin’s lymphoma: multistate illness-death model. Int J Hematol Oncol Stem Cell Res 12(1):57–64

    PubMed  PubMed Central  Google Scholar 

  21. Ahmadzadeh A, Yekaninejad MS, Jalili MH, Bahadoram M, Efazat M, Seghatoleslami M, Yazdi F, Mahdipour M, Valizadeh A, Saki N (2014) Evaluating the survival rate and the secondary malignancies after treating Hodgkin’s lymphoma patients with chemotherapy regimens. Int J Hematol Oncol Stem Cell Res 8(2):21–26

    PubMed  PubMed Central  Google Scholar 

  22. Gaudio F, Pedote P, Asabella AN, Perrone T, Laddaga FE, Sindaco P, Cimmino A, D'Abbicco D, Pezzolla A, Rubini G, Specchia G (2018) Extralymphatic disease is an independent prognostic factor in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 18(6):e261–e266. https://doi.org/10.1016/j.clml.2018.04.001

    Article  PubMed  Google Scholar 

  23. Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L, Semenzato G (1987) Soluble interleukin-2 receptors in the serum of patients with Hodgkin’s disease. Br J Cancer 55(4):427–428

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(4):331–344. https://doi.org/10.1056/NEJMoa1708984

    Article  CAS  PubMed  Google Scholar 

  25. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Huttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kuhnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A (2018) PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790–2802. https://doi.org/10.1016/s0140-6736(17)32134-7

    Article  Google Scholar 

  26. Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T (2012) Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res 32(11):5051–5057

    CAS  PubMed  Google Scholar 

  27. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol Off J Am Soc Clin Oncol 25(24):3746–3752. https://doi.org/10.1200/jco.2007.11.6525

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan

    Kento Umino, Shin-ichiro Fujiwara, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi & Yoshinobu Kanda

Authors
  1. Kento Umino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin-ichiro Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shin-ichiro Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumiko Toda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoko Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shin-ichi Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Nagayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kiyomi Mashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daisuke Minakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirofumi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ryoko Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kaoru Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasufumi Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Chihiro Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Masahiro Ashizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kaoru Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Kazuya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Iekuni Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Ken Ohmine
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Kazuo Muroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Yoshinobu Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshinobu Kanda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this retrospective study, formal informed consent is not required. This study was approved by the ethics committee of Jichi Medical University and performed in accordance with the Declaration of Helsinki and its later amendments.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Umino, K., Fujiwara, Si., Ikeda, T. et al. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy. Ann Hematol 98, 2121–2129 (2019). https://doi.org/10.1007/s00277-019-03738-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03738-3

Keywords

Search

Navigation